Edoxaban

CHEMBL1269025 Phase 4 Disetujui Small molecule

Half-Life

10-14 hours

Bioavailability

—

Protein Binding

—

Molecular Weight

548.1 g/mol

LogP

1.4

Phase

4

A direct oral anticoagulant that inhibits factor Xa, a key protein in the blood clotting cascade, used to prevent stroke in patients with atrial fibrillation and to treat blood clots in veins. It does not require routine blood monitoring unlike older blood thinners.

Berat Molekul

548,0530 g/mol

LogP

1,40

TPSA

165,00 Å²

Lipinski RO5

Lulus

Area Terapeutik

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Non-Small Cell Lung Cancer Chronic Kidney Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Type 2 Diabetes Hypertension Breast Cancer Heart Failure Atrial Fibrillation Prostate Cancer Colorectal Cancer

Kelas Obat

B — B - Blood and Blood Forming Organs

Mekanisme Kerja

Direct, selective inhibitor of Factor Xa preventing thrombin generation and clot formation.

Pharmacokinetics (PK)

Half-Life 10-14 hours

Pharmacodynamics (PD)

Mekanisme

Direct, selective inhibitor of Factor Xa preventing thrombin generation and clot formation.

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1

InChI

InChI=1S/C24H30ClN7O4S/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34)/t13-,15-,17+/m0/s1

Molecular Formula

C24H30ClN7O4S

HBD / HBA

3 / 8

Ikatan yang Dapat Dirotasi

5

Atom Berat

37

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A direct oral anticoagulant that inhibits factor Xa, a key protein in the blood clotting cascade, used to prevent stroke in patients with atrial fibrillation and to treat blood clots in veins. It does not require routine blood monitoring unlike older blood thinners.

Direct, selective inhibitor of Factor Xa preventing thrombin generation and clot formation.

Key pharmacokinetic parameters for Edoxaban: Half-life: 10-14 hours.

Yes, Edoxaban is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

Same Drug Class

Warfarin Small molecule Clopidogrel Small molecule Apixaban Small molecule Rivaroxaban Small molecule

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1269025. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 10280735. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Mencari informasi yang ramah bagi pasien?

Edoxaban di PillFYI

Struktur

Data Cepat

Class: B - Blood and Blood Forming Organs
Rumus: C24H30ClN7O4S
Sinonim: 1

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Edoxaban

Area Terapeutik

Kelas Obat

Mekanisme Kerja

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

Cite this structure

Embed this structure

No targets recorded

No interactions recorded

No side effects recorded

Pertanyaan yang Sering Diajukan

Related Drugs

Same Drug Class

References & Data Sources

Embed This Widget